Introduction:

This preprint review follows specific guidelines provided by the Publons team to secure rapid critical appraisals of preprints related to the COVID-19 outbreak. My assessment scrutinises this paper for sound scientific practices, in the hope that this will help researchers working on the COVID-19 outbreak.

Brief overview of the paper and its main findings:

This Paper discloses the concept of Drug re-purposing for covid-19.

Reviewer type:

I am not currently working directly on the COVID-19 response, but I consider myself an expert in the methods and core concepts used in this paper.

COVID-19 Topic

Drug Modelling (Docking study)

Author/s’ experience:

The authors have experience and have published a couple of articles in topics related to molecular docking. The study is not concluded with all the necessary evidence.

Methodology

The study does not give any details about the Pharmacokinetics. An in-vitro study of the drug is required for the conclusion.

Research integrity:

No evidence of potential plagiarism, misconduct (such as data falsification or fabrication), or other ethical implications such as lacking ethics approval for animal/human studies have been noticed.

Conflicts of interest: No conflict of interest arises in this review.

Basis of the findings:

• Majorly the study depends upon the drugs that are previously used as antiviral agents.

• Based on drug re-purposing, the antiviral agents studied in this experiment has shown positive results in inhibiting the covid-19 molecules.

• The study is based upon molecular docking using Maestro interface. Therefore, more information is required to conclude the molecules as a potential drug for treatment.

• In-vitro study details and the drug’s Pharmacokinetics must be disclosed for the conclusion of the therapeutic.

Overall categorization:

Incremental. As best as you can assess, this paper validates or summarizes other research to-date and does not promise any substantial breakthrough/s in COVID-19 research.